Vivoryon Therapeutics Prepares for Key Financial Reporting Events

Author: Kelly Martin Updated: 10-09-2025 10:54 PM

Upcoming Financial Reporting and KOL Event

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a clinical-stage biotechnology company dedicated to creating innovative small molecule medicines, is preparing to share important updates this September. The company focuses on modulating the activity and stability of proteins that are pathologically altered, with the aim of addressing serious diseases.

Half Year 2024 Financial Results

On September 12, Vivoryon will release its financial results for the first half of 2024, along with a corporate update. This announcement will be accompanied by a conference call and a public webcast. Investors and interested individuals are encouraged to visit the company's official website to access the report and stay updated on its progress and strategic initiatives.

Conference Call Details

The conference call is set for 3:00 PM CEST, which is 9:00 AM EDT. Participants are recommended to join the call 15 minutes early to ensure a smooth connection.

Virtual Kidney Disease KOL Event

Alongside the financial update, Vivoryon will conduct a virtual event centered on Kidney Disease on September 30. This event aims to gather key opinion leaders in the field, fostering discussions about the latest advancements and therapeutic strategies in kidney healthcare.

Event Schedule

The virtual event will begin at 3:00 PM CEST / 9:00 AM EDT, offering medical professionals a chance to engage with Vivoryon and explore innovative solutions for kidney diseases.

About Vivoryon Therapeutics N.V.

Vivoryon Therapeutics is committed to improving lives through the development of small molecule-based therapies. With a strong pipeline that includes treatments for Alzheimer’s disease and various inflammatory conditions, the company leverages its deep understanding of post-translational modifications to create effective medicinal solutions. Their research initiatives are significantly impacting patient care and addressing unmet medical needs in serious health conditions.

Recent Developments

The company is consistently investing in research and development to broaden its therapeutic portfolio. Vivoryon is particularly focused on small molecule inhibitors that address critical health issues, ensuring that innovative treatment options are accessible to those who need them. As the biotechnology landscape evolves, Vivoryon is well-positioned to lead with its innovative strategies and dedication to patient care.

Frequently Asked Questions

What are the key events hosted by Vivoryon Therapeutics in September?

Vivoryon will host a financial results announcement on September 12 and a virtual Kidney Disease KOL event on September 30.

How can I access the financial results report?

The financial report will be available for download on Vivoryon's official website on the date of the announcement.

What is the focus of Vivoryon Therapeutics?

Vivoryon focuses on developing small molecule medicines that modulate the activity of proteins altered in disease, targeting conditions like Alzheimer's and kidney diseases.

When is the conference call for the financial results?

The conference call will take place on September 12 at 3 PM CEST / 9 AM EDT.

What happens during the virtual KOL event?

The virtual event will facilitate discussions among key opinion leaders regarding advancements in kidney disease treatment, encouraging knowledge exchange within the medical community.

About The Author

Hello Kelly Martin here, a financial and publicly traded company specialist committed to writing with clarity and sage advice. Having a wealth of experience and a thorough grasp of corporate dynamics and the financial environment, my main goal in writing blog posts and articles is to provide insightful analysis together with useful guidance. My objective is to arm readers with the information they need to comprehend the complexities of publicly traded companies and make wise financial decisions.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors to seasoned pros looking for fresh perspectives. My goal is to make corporate analysis and finance understandable and interesting so you may confidently negotiate the intricacies of the financial world. I appreciate you traveling with me toward success and financial literacy.

Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.